Drug makeover: When a drug underperforms, Big Pharma renames it, labels it for another use and jacks up the price

(Natural News) A drug that treats periodic paralysis may be pricing those afflicted with the condition out of the market. Originally a medicine approved for glaucoma treatment, the U.K. National Health Service made Daranide available for the equivalent of about $500 U.S. dollars for a year’s supply. Daranide reportedly didn’t work well for the eye disease,…

Read Original Article: Drug makeover: When a drug underperforms, Big Pharma renames it, labels it for another use and jacks up the price »

Powered by WPeMatico